Do natural variations in hormones, such as oestrogen, make anxiety disorders more likely? If so does this affect the way people respond to treatment?
Genetic and genomic drivers of network phenotypes in health and disease
Dr Petra Vértes is looking at what’s going on in the brain when symptoms of schizophrenia first arise so we can create novel targeted treatments.
The project
Schizophrenia affects 1% of the population and has life-long impacts. Our understanding of the brain processes behind the condition remain limited, meaning it’s difficult to treat.
We know that the brain undergoes huge reorganisation during teenage years and schizophrenia often first arises during this period. But we don’t yet have a clear understanding of the specific mechanisms going awry and the genes that could be responsible for them.
Dr Petra Vertes and her team at the University of Cambridge are looking at genetic data and brain scans to uncover the biological processes responsible for psychosis and other symptoms experienced by people with schizophrenia.
The process
To begin her research, Petra will analyse brain scans collected from hundreds of ‘healthy’ volunteers, people who have already experienced psychosis, and a group of people who have been identified to be at risk.
These scans will reveal the patterns in the brain that could be unique to schizophrenia and those at risk.
But these patterns can only tell us so much – in order to improve treatments, we need to understand what they mean biologically.
To do this, Petra will cross-reference her scans with the Allen Brain Atlas. The Atlas took over a decade to compile and it maps the activity of all known genes across the entire brain. Once she’s got the relevant genetic information, she’ll be able to further understand which biological processes could be disrupted in schizophrenia.
Her work will give her a window into what’s happening in the brain as it develops during adolescence and, crucially, what’s different for people who grow to have symptoms of schizophrenia.
The potential
Petra’s study offers vital knowledge into the emergence of schizophrenia at a biological level, highlighting which molecules and genes are important. Although drug treatments for schizophrenia are available, they tend only to work for some symptoms and don’t work at all for a significant number of patients.
This understanding provides the basis to create better treatments that target important networks in the brain so we can improve the lives of people facing schizophrenia.
Supported by the Stephen Palmer Fellowship fund.
Dr Petra Vértes is a researcher in the Department of Psychiatry, her work focuses on understanding brain networks.
Was this information helpful?
Related research profiles
Sensitive periods for the effects of depression on suicide risk: a longitudinal study of gene-environment interactions and epigenetic mechanisms
Dr Lussier aims to determine the extent to which child and adolescent depression interacts with genetic susceptibility to influence suicide risk in early adulthood.
Increasing access to social prescribing for people living with severe mental illnesses at risk of cardiovascular disease
People with severe mental illnesses are at high risk of heart disease due to lack of physical activity and social isolation. Social prescribing can help, but is it accessible?